WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Thursday, February 25, 2021 
Add Press Release News | News Feeds Feeds | Email This News Email


Global AI-based Drug Discovery Market Report 2021: Current Market Landscape and Future Potential of the Players Engaged in Offering AI-Based Services, Platforms and Tools - Forecast to 2030
Thursday, February 25, 2021

DUBLIN, Feb. 19, 2021 /PRNewswire/ -- The "AI-based Drug Discovery Market: Focus on Deep Learning and Machine Learning, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The "AI-based Drug Discovery Market: Focus on Machine Learning and Deep Learning, 2020-2030" report features an extensive study of the current market landscape and future potential of the players engaged in offering AI-based services, platforms and tools for the discovery of novel drug candidates. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

The drug discovery process, which includes the identification of a relevant biological target and a corresponding pharmacological lead, is crucial to the clinical success of a drug candidate.

Considering the growing complexity of modern pharmacology, the discovery of viable therapeutic candidates is very demanding, both in terms of capital investment and time. In fact, according to a study conducted by Tufts Center for the Study of Drug Development, it was estimated that a prescription drug requires around 10 years and over USD 2.5 billion in capital investment, while traversing from the bench to the market. Around one-third of the aforementioned expenditure is incurred during the drug discovery phase alone.

Moreover, it is well-known that only a small proportion of pharmacological leads identified during the discovery stages are actually translated into viable product candidates for clinical studies. Currently, experts believe that close to 90% of the product candidates fail to make it past the clinical stage of development. This high attrition rate has long been attributed to the legacy drug discovery process, which is more of a trial-and-error paradigm.

In attempts to address the concerns associated with rising capital requirements in drug discovery, and prevent late stage failure of drug development programs, stakeholders in the pharmaceutical industry are currently exploring the implementation of Artificial Intelligence (AI) based tools in order to better inform drug development operations using available chemical and biological data.

A detailed review of the current market landscape of companies that claim to offer AI-based services, platforms and tools for drug discovery. It includes information on year of establishment, company size (in terms of number of employees), location of headquarters, number of AI-based platforms/tools available, type of AI technology used, drug discovery steps for which the company has expertise involving the use of AI (target identification/validation, lead identification/optimization and ADMET studies), type of drug molecule handled (small molecules, biologics and both), drug development initiatives undertaken by the firm and target therapeutic area.

One of the key objectives of this report was to estimate the existing market size and the future growth potential within the AI-based drug discovery market. We have developed informed estimates on the financial evolution of the market, over the period 2020-2030.

Key Questions Answered

    --  Who are the leading players engaged in the AI-based drug discovery
        market?
    --  Which key AI technologies are presently being most commonly adopted by
        drug discovery focused companies?
    --  What is the likely valuation/net worth of companies engaged in this
        domain?
    --  What is the likely cost saving potential associated with the use of AI
        in the drug discovery process?
    --  Which partnership models are most commonly adopted by stakeholders
        engaged in this industry?
    --  What is the overall trend of funding and investments within this domain?
    --  How is the current and future opportunity likely to be distributed
        across key market segments?

Companies Mentioned

    --  3BIGS
    --  3W Partners
    --  6 Dimensions Capital
    --  8VC
    --  99andBeyond
    --  A2A Pharmaceuticals
    --  Abalone Bio
    --  AbbVie
    --  AbCellera
    --  Abstract Ventures
    --  Accelerate Long Island
    --  Accenture
    --  Accutar Biotech
    --  Acellera
    --  Acequia Capital
    --  AcuraStem
    --  Adagene
    --  ADC Therapeutics
    --  ADEL
    --  Advantage Capital
    --  AdynXX
    --  Agent Capital
    --  AGORANO
    --  AI Therapeutics
    --  Ai-biopharma
    --  Aigenpulse
    --  Air Street Capital
    --  Ajou University
    --  Akashi Therapeutics
    --  Albany Molecular Research
    --  A-Level Capital
    --  Alexandria Real Estate Equities
    --  Alibaba Cloud
    --  Allergan
    --  Alliance for Clinical Trials in Oncology
    --  Alloy Therapeutics
    --  Almac Diagnostic Services
    --  Almirall
    --  Alphanosos
    --  ALS Association
    --  ALS Investment Fund
    --  Altos Ventures
    --  Amadeus Capital Partners
    --  Amadeus Capital Partners
    --  Amazon Web Services
    --  Amazon Web Services (AWS)
    --  AME Cloud Ventures
    --  American Society of Clinical Oncology
    --  Amgen
    --  Amgen Ventures
    --  Amidi Group
    --  Amplify Partners
    --  Amplitude
    --  Anagenesis Biotechnologies
    --  Andreessen Horowitz
    --  Angel CoFund
    --  Anima Biotech
    --  Ansa Biotechnologies
    --  Antiverse
    --  ApexQubit
    --  Aqemia
    --  Arbutus Biopharma
    --  ARCH Venture Partners
    --  ArcTern Ventures
    --  Arctoris
    --  Ardigen
    --  Arpeggio Biosciences
    --  Artis Ventures
    --  Arzeda
    --  Asset Management Ventures
    --  Astellas Pharma
    --  Astia Angels
    --  AstraZeneca
    --  AstraZeneca's Centre for Genomics Research
    --  ATAI Life Sciences
    --  Atinum Investment
    --  Atlantic Labs
    --  Atlas Venture
    --  Atomico
    --  Atomwise
    --  Atrius Health
    --  AUM Biosciences
    --  Auransa
    --  Aurinvest
    --  Auvergne-Rhone-Alpes regional council
    --  AVIC Trust
    --  AxoSim
    --  B Capital Group
    --  BABEL Ventures
    --  Baidu Ventures
    --  Baillie Gifford
    --  Balderton Capital
    --  Bangarang Group
    --  Battelle Center for Science, Engineering, and Public Policy, Ohio State
        University
    --  Bavarian Nordic
    --  Bayer
    --  Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC)
    --  Beiersdorf
    --  Benevolent AI
    --  BERG
    --  Better Ventures
    --  Bezos Expeditions
    --  Big Data Institute
    --  BigHat Biosciences
    --  Bill & Melinda Gates Foundation
    --  BioAge Labs
    --  Bioeconomy Capital
    --  BioFocus DPI
    --  BioInvent International
    --  Biomea Healthcare
    --  BioMotiv
    --  Bionano Genomics
    --  BioNTech
    --  Biorelate
    --  Bios Partners
    --  BioSymetrics
    --  biotx.ai
    --  BioVentures Investors
    --  Bioverge
    --  Biovista
    --  BioXcel Therapeutics
    --  BlackRock
    --  Block.one
    --  Bloomberg Beta
    --  Blue Bear Ventures
    --  bluebird bio
    --  Boehringer Ingelheim
    --  Bold Capital Partners
    --  Bpifrance
    --  Brace Pharma Capital
    --  Brain Canada
    --  Breakout Labs
    --  BridgeBio Pharma
    --  Brigham and Women's Hospital
    --  Brightspark Ventures
    --  Bristol-Myers Squibb
    --  Broad Institute
    --  btov Partners
    --  Builders VC
    --  Bulba Ventures
    --  Busolantix Investment
    --  BVF Partners
    --  C4X Discovery
    --  Caffeinated Capital
    --  Calibr
    --  California Institute of Biomedical Research
    --  Cambia Health Solutions
    --  Cambridge Cancer Genomics
    --  Cambridge Research Centre
    --  Cancer Genetics
    --  Cantos Ventures
    --  CARB-X
    --  CareDx
    --  CaroCure
    --  Casdin Capital
    --  Catalio Capital Management
    --  Catapult Ventures
    --  Cathay Innovation
    --  Causaly
    --  CB Lux
    --  CECS
    --  Celgene
    --  Cellarity
    --  Celsius Therapeutics
    --  Center for the Advancement of Science in Space
    --  CENTOGENE
    --  Centre for the Development of Industrial Technology (CDTI)
    --  Cerebras
    --  Cerevel Therapeutics
    --  Charcot-Marie-Tooth Association
    --  Charles River Laboratories
    --  ChemAlive
    --  ChemAxon
    --  ChemDiv
    --  ChemPass
    --  ChemSpace
    --  Chiesi Farmaceutici
    --  Children's Tumor Foundation
    --  China Canada Angels Alliance
    --  China International Capital Corporation
    --  China Life Healthcare Fund
    --  China Oncology Focus
    --  Chinese Academy of Medical Sciences
    --  Cigna Ventures
    --  City Hill Ventures
    --  Civilization Ventures
    --  CJ HealthCare
    --  Claremont Creek Ventures
    --  Clarus Ventures
    --  Cleveland Clinic
    --  CLI Ventures
    --  Climate-KIC Accelerator
    --  Cloud Pharmaceuticals
    --  CMT Research Foundation
    --  Collaborations Pharmaceuticals
    --  Collaborative Drug Discovery
    --  Collective Scientific
    --  Colt Ventures
    --  ConcertAI
    --  Conifer Point Pharmaceuticals
    --  Cormorant Asset Management
    --  Cosine
    --  Cota Capital
    --  CPP Investments
    --  CQDM - Consortium de recherche biopharmaceutique
    --  Creative Destruction Lab
    --  Cresset
    --  CrystalGenomics
    --  CTI Life Sciences Fund
    --  Cultivian Sandbox Ventures
    --  CVC
    --  CVS Health
    --  Cyclica
    --  CytoReason
    --  Daewoong Pharmaceutical
    --  Danhua Venture Capital
    --  Dante Labs
    --  Data4cure
    --  Dataspora
    --  Datavant
    --  DCVC
    --  DEARGEN
    --  Deep Genomics
    --  Deep Knowledge Ventures
    --  DeepCure
    --  DeepMatter
    --  DeepTrait
    --  Deerfield Management
    --  Delin Ventures
    --  Denali Therapeutics
    --  Denovicon Therapeutics
    --  Denovium
    --  Department of Health and Social Care
    --  DEXSTR
    --  Diamond Light Source
    --  DNAnexus
    --  DNDi
    --  Dolby Family Ventures
    --  Dow AgroSciences
    --  Drive Capital
    --  Droia Oncology Ventures
    --  DSC Investment
    --  Dualogics
    --  Dynamk Capital
    --  Dyno Therapeutics
    --  Echo Health Ventures
    --  EcoR1 Capital
    --  EDBI
    --  EIC Accelerator
    --  Eight Roads
    --  Elad Gil
    --  Elaia
    --  Elevian
    --  Eli Lilly
    --  Elsevier
    --  Elucidata
    --  Embark Ventures
    --  Empire State Development
    --  Empirico
    --  Enamine
    --  Endogena Therapeutics
    --  Endure Capital
    --  Engine Biosciences
    --  Enterprise Ireland
    --  Envisagenics
    --  Epic Capital Management
    --  Epic Ventures
    --  Erasca
    --  e-therapeutics
    --  Euretos
    --  European Investment Bank
    --  European Union
    --  Eurostars
    --  Evaxion Biotech
    --  Evotec
    --  Ewha Womans University
    --  Excelra
    --  Executive Agency for Small and Medium-sized Enterprises (EASME)
    --  Exscientia
    --  Felicis Ventures
    --  Fidelity Asia Fund
    --  Fidelity Biosciences
    --  Fifty Years
    --  Financiere Boscary
    --  FinLab
    --  First Round Capital
    --  First Star Ventures
    --  Flagship Pioneering
    --  Flybridge Capital Partners
    --  FMC
    --  Foresite Capital
    --  Forma Therapeutics
    --  Formic Ventures
    --  Foundation for Angelman Syndrome Therapeutics (FAST)
    --  Founders Factory
    --  Founders Fund
    --  Fountain Therapeutics
    --  Fox Chase Cancer Center
    --  F-Prime Capital
    --  FREES FUND
    --  Frontier Medicines
    --  FundersClub
    --  Future Ventures
    --  G3 Therapeutics
    --  Galapagos
    --  Gatehouse Bio
    --  GC Pharma
    --  Geisinger
    --  Genedata
    --  Genentech
    --  General Atlantic
    --  General Catalyst
    --  Genesen
    --  Genesis Therapeutics
    --  Genialis
    --  Genmab
    --  Genomatica
    --  Genome Biologics
    --  Genome Institute of Singapore
    --  Genomenon
    --  Genomics England
    --  Genuity Science
    --  Gero
    --  Gi Global Health Fund
    --  Gilead Sciences
    --  GlaxoSmithKline
    --  Global Brain
    --  Global Founders Capital
    --  GM&C Life Sciences Fund
    --  GNS Healthcare
    --  Golden Ventures
    --  Google
    --  Google Ventures
    --  Gopher Asset Management
    --  Gordian Biotechnology
    --  Government of Canada
    --  Government of Switzerland
    --  GP Healthcare Capital
    --  GPG Ventures
    --  Grand Challenges Canada
    --  Green Park & Golf Ventures
    --  GreenSky Capital
    --  Gritstone Oncology
    --  GT Healthcare Capital Partners
    --  Gustave Roussy
    --  Hafnium Labs
    --  Hanhai Studio
    --  Harbour Antibodies
    --  Harbour BioMed
    --  Harris & Harris Group
    --  HCS
    --  Health Wildcatters
    --  HealthInc
    --  Healx
    --  Heritage Provider Network
    --  Hewlett Packard Enterprise (HPE)
    --  Hibiskus Biopharma
    --  Hike Ventures
    --  Hinge Therapeutics
    --  Hiventures Investment Fund
    --  HOF Capital
    --  HotSpot Therapeutics
    --  Huadong Medicine
    --  Human Capital
    --  Hyperplane Venture Capital
    --  IA Ventures
    --  IBM
    --  Ichor Biologics
    --  IDG Capital
    --  IIT Kharagpur
    --  Iktos
    --  IMM Investment
    --  Immunocure Discovery Solutions
    --  InfoChem
    --  InnoPharmaScreen
    --  Innophore
    --  Innoplexus
    --  Innospark Ventures
    --  Innova31
    --  Innovate NY Fund
    --  Innovate UK
    --  Innovation Endeavors
    --  Innovation Fund Denmark
    --  Innovative Medicines Initiative (IMI)
    --  Inovia Capital
    --  inSili.com
    --  Insiliance
    --  Insilico Medicine
    --  Insitro
    --  Institut Carnot CALYM
    --  Institut Gustave Roussy
    --  Institut Pasteur Korea
    --  Institute of Cancer Research, London
    --  Institute of Materia Medica
    --  Intel
    --  Intel Capital
    --  Intellegens
    --  IntelliCyt
    --  Intermountain Ventures
    --  Interprotein
    --  Intuition Systems
    --  InveniAI
    --  InVivo AI
    --  Invus
    --  Ionis
    --  IP Group
    --  IPF Partners
    --  IQVIA
    --  Ireland Strategic Investment Fund
    --  I-Stem
    --  IT-Translation
    --  Janssen Pharmaceutica
    --  Jiangsu Chia Tai Fenghai Pharmaceutical
    --  Jiangsu Hansoh Pharmaceutical Group
    --  JLABS
    --  Johns Hopkins School of Medicine
    --  Johns Hopkins University
    --  Johnson & Johnson
    --  Johnson & Johnson Innovation - JJDC
    --  Juvena Therapeutics
    --  Juvenescence
    --  JW Pharmaceutical
    --  K Cube Ventures
    --  K9 Ventures
    --  KB Securities
    --  Kebotix
    --  Keio University
    --  KemPharm
    --  Khosla Ventures
    --  Kindred Capital
    --  Kinetic Discovery
    --  King Star Capital
    --  King's College London
    --  Korea Atomic Energy Research Institute (KAERI)
    --  Korea Development Bank
    --  Korea Fixed-Income Investment Advisory
    --  Korea Investment Partners
    --  Korea Research Institute of Chemical Technology (KRICT)
    --  Ksilink
    --  KTB Network
    --  La Financiere Gaspard
    --  Labcyte
    --  LabGenius
    --  LabKey
    --  Lansdowne Partners
    --  Lantern Pharma
    --  LanzaTech
    --  Laurion Capital Management
    --  Lawrence Livermore National Laboratory
    --  Laxai Life Sciences
    --  LB Investment
    --  Leaps by Bayer
    --  LEO Pharma
    --  Lhasa
    --  LifeForce Capital
    --  LifeSci Venture Partners
    --  Lightspeed Venture Partners
    --  Lilly Asia Ventures
    --  Linguamatics
    --  LMU University Hospital
    --  Lodo Therapeutics
    --  Long Island Emerging technologies Fund (LIETF)
    --  Longevity Fund
    --  Loup Ventures
    --  Lundbeck
    --  Lux Capital
    --  Luxembourg Centre for Systems Biomedicine (LCSB)
    --  M12
    --  MAbSilico
    --  Macroceutics
    --  Magnetic Ventures
    --  Manchester Tech Trust Angels
    --  Mannin Research
    --  Marathon Venture Capital
    --  MaRS Catalyst Fund
    --  Maruho
    --  Massachusetts Life Sciences Center
    --  MassBiologics
    --  Maxygen
    --  MBC BioLabs
    --  McQuibban Lab
    --  MDS Foundation
    --  Medchemica
    --  Medical Prognosis Institute
    --  Medirita
    --  Memorial Sloan Kettering Cancer
    --  Menlo Ventures
    --  Menten AI
    --  Merck
    --  Merck Accelerator
    --  Mercury Fund
    --  Meridian Street Capital
    --  Micar Innovation
    --  Michael J. Fox Foundation
    --  Microsoft
    --  Microsoft Ventures
    --  MidCap Financial
    --  Mila
    --  Mirae Asset Venture Investment
    --  MIT delta v
    --  Mitsui
    --  Molecule
    --  Molecule.one
    --  Moleculomics
    --  Molomics
    --  Monsanto Growth Ventures
    --  MPM Capital
    --  MRL Ventures Fund
    --  Mubadala Capital
    --  Multiple Myeloma Research Foundation
    --  Muscular Dystrophy Association
    --  Muscular Dystrophy UK
    --  myTomorrows
    --  Nan Fung Life Sciences
    --  Nanna Therapeutics
    --  Nashville Biosciences
    --  National Cancer Institute
    --  National Center for Advancing Translational Sciences ( NCATS )
    --  National Center for Research and Development
    --  National Institute of Neurological Disorders and Stroke (NINDS)
    --  National Institute on Aging (NIA)
    --  National Institutes of Health
    --  National Institutes of Small Business Technology Transfer
    --  National Instrumentation Center for Environmental Management
    --  National Research Council Canada
    --  National Science Foundation
    --  National Science Foundation Small Business Innovation Research (NSF
        SBIR) program
    --  Nektar Therapeutics
    --  Nest.Bio Ventures
    --  Nestle
    --  Neuropore Therapies
    --  NeuroTheryX
    --  New Protein Capital
    --  New Wave Ventures
    --  New World TMT
    --  New York Medical College
    --  NewDo Venture
    --  Nex Cubed
    --  nference
    --  NJF Capital
    --  Nonacus
    --  Northpond Ventures
    --  Notable Labs
    --  Novartis
    --  Novo Holdings
    --  Novo Nordisk
    --  NPIF - Maven Equity Finance
    --  Numedii
    --  Nuritas
    --  NVIDIA
    --  O2h Ventures
    --  Oak Ridge National Laboratory
    --  Obvious Ventures
    --  OCA Ventures
    --  OccamzRazor
    --  Octopus Ventures
    --  Olaris
    --  Oncologie
    --  OncoStatyx
    --  One Way Ventures
    --  OneThree Biotech
    --  Ono Pharmaceutical
    --  Optibrium
    --  Optum Venture
    --  OrbiMed
    --  OS Fund
    --  OSE Immunotherapeutics
    --  OSEO
    --  Overkill Ventures
    --  OVP Venture Partners
    --  OWKIN
    --  Oxford Drug Design
    --  Panache Ventures
    --  PAREXEL
    --  Parinvest
    --  Parker Institute for Cancer Immunotherapy
    --  Parkinson's UK
    --  Partner Fund Management
    --  Pavilion Capital
    --  PEACCEL
    --  Pear VC
    --  PENDING.AI
    --  Pentech Ventures
    --  Peptone
    --  Peptris Technologies
    --  PercayAI
    --  Perceptive Advisors
    --  Pfizer
    --  Pfizer Venture Investments
    --  Pharmacelera
    --  Pharmavite
    --  PharmCADD
    --  PharmEnable
    --  Pharnext
    --  Pharos iBio
    --  Phenomic AI
    --  PhoreMost
    --  Pi Campus
    --  PIKAS d.o.o.
    --  Plex Research
    --  Plug and Play Ventures
    --  Polaris Partners
    --  Polaris Quantum Biotech
    --  Polyclone Bioservices
    --  Porton
    --  PostEra
    --  PrecisionLife
    --  Predictive Oncology
    --  Prefix Capital
    --  Presight Capital
    --  Primary Venture Partners
    --  Prime Movers Lab
    --  Primordial Genetics
    --  Prism Pharma
    --  Promega
    --  Propagator Ventures
    --  ProteinQure
    --  ProteiQ Biosciences
    --  QIAGEN
    --  Qiming Venture Partners
    --  Quantitative Medicine
    --  Qulab
    --  RA Capital Management
    --  Radical Ventures
    --  Rahko
    --  Ramen Ventures
    --  RaQualia Pharma
    --  Real Ventures
    --  RealHealthData
    --  Recursion Pharmaceuticals
    --  Redalpine
    --  Redbiotec
    --  Redmile Group
    --  Redpoint Ventures
    --  Refactor Capital
    --  Regeneron Pharmaceuticals
    --  Regional Cancer Centre (RCC)
    --  Relation Therapeutics
    --  Relay Therapeutics
    --  Remedium AI
    --  RenalytixAI
    --  Reneo Capital
    --  Renren
    --  ReproCell
    --  Repurpose.AI
    --  Research Triangle Park
    --  Resonant Therapeutics
    --  Reverie Labs
    --  ReviveMed
    --  Rigetti Computing
    --  Rising Tide
    --  Rivas Capital
    --  Roche
    --  Romulus Capital
    --  Rough Draft Ventures
    --  RT Partners
    --  Samsara BioCapital
    --  Sanabil Investments
    --  Sanofi
    --  Sanofi
    --  Santen Pharmaceutical
    --  Saphetor
    --  Sapio Sciences
    --  Sapir Venture Partners
    --  Sarepta Therapeutics
    --  SARomics Biostructures
    --  Saverna Therapeutics
    --  Schrodinger
    --  SciFi VC
    --  Scripps Research
    --  Sea Lane Ventures
    --  Searchbolt
    --  Selvita
    --  Sema4
    --  SEngine Precision Medicine
    --  Seoul National University
    --  Sequoia Capital
    --  Sequoia China
    --  Seraph Group
    --  Serra Ventures
    --  Servier
    --  Siemens
    --  SIG
    --  Sinequa
    --  Sinopia Biosciences
    --  Sinovation Ventures
    --  Sirenas
    --  SK Biopharmaceuticals
    --  SK Holdings
    --  Smilegate Investment
    --  Sofinnova Partners
    --  SoftBank Ventures
    --  SoftTech VC
    --  Solasta Ventures
    --  SolveBio
    --  SOM Biotech
    --  Soma Capital
    --  SOSV
    --  SparkBeyond
    --  Spektron Systems
    --  Spring Discovery
    --  Square 1 Bank
    --  SR One
    --  SRI International
    --  Stage Venture Partners
    --  Standigm
    --  Stanford University
    --  StarFinder
    --  Startupbootcamp
    --  StartX Fund
    --  Stemmore
    --  StemoniX
    --  Stonehaven
    --  Structura Biotechnology
    --  Sunfish Partners
    --  Sunwest Bank
    --  Susa Ventures
    --  Sustainable Conversion Ventures
    --  Sutter Health
    --  SV Angel
    --  Synsight
    --  Syntekabio
    --  Synthelis
    --  Systems Oncology
    --  Taisho Pharmaceutical
    --  Takeda Development Center Americas
    --  Takeda Pharmaceutical
    --  Tanabe Research Laboratories
    --  Tanarra
    --  TARA Biosystems
    --  Tasly Pharmaceutical
    --  Tavistock Group
    --  TB Alliance
    --  Team Builder Ventures
    --  Techammer
    --  TechU
    --  Tekla Capital Management
    --  Temasek Holdings
    --  TenOneTen Ventures
    --  Terra Magnum Capital Partners
    --  TeselaGen
    --  Teva Pharmaceuticals
    --  TF Bioinformatics
    --  The Buck Institute and
    --  The Column Group
    --  The Cure Parkinson's Trust (CPT)
    --  The Edge Software Consultancy
    --  The Longevity Fund
    --  The Partnership Fund for New York City
    --  The Pritzker Organization
    --  The Yozma Group Korea
    --  THERAMetrics
    --  Third Kind Venture Capital
    --  Third Rock Ventures
    --  Three Lakes Partners
    --  Threshold Ventures
    --  Tillotts Pharma
    --  Timewise Investment
    --  Top Technology Ventures
    --  Topspin Fund
    --  Toyohashi University of Technology
    --  TPG Biotech
    --  TPG Capital
    --  Transcriptic
    --  Transilico
    --  Translational Medicine Accelerator
    --  Trinitas Capital
    --  True Ventures
    --  Truffle Capital
    --  TSVC
    --  Turbine.AI
    --  Twin Ventures
    --  Two Sigma Ventures
    --  twoXAR Pharmaceuticals
    --  U.S. Securities and Exchange Commission (SEC)
    --  UC Riverside
    --  UK Biobank
    --  Uncork Capital
    --  Uni-innovate group
    --  Universal Materials Incubator
    --  University College London
    --  University Health Network
    --  University Hospital Institute Mediterranee Infection
    --  University of California
    --  University of Chicago
    --  University of Connecticut
    --  University of Groningen
    --  University of Kentucky
    --  University of Leeds
    --  University of Manitoba
    --  University of Miami
    --  University of Michigan College of Pharmacy
    --  University of Michigan Life Sciences
    --  University of Minnesota
    --  University of Nottingham
    --  University of Oxford
    --  University of Pittsburgh
    --  University of Toronto
    --  University of Wisconsin-Milwaukee Research Foundation
    --  University of North Carolina
    --  Unnatural Products
    --  UPPthera
    --  Upsher-Smith Laboratories
    --  VantAI
    --  Verge Genomics
    --  VeriSIM
    --  Versant Ventures
    --  Viking Global Investors
    --  Village Global
    --  Vingyani
    --  Vir Biotechnology
    --  VisVires New Protein
    --  Vium
    --  Vlaams Instituut voor Biotechnologie (VIB)
    --  VYASA Analytics
    --  Watson Fund
    --  Wave
    --  Wheatsheaf Group
    --  WI Harper
    --  Wild Basin Investments
    --  Wiley
    --  Wisecube
    --  Woodford Investment Management
    --  WorldQuant Ventures
    --  WRF Capital
    --  WuXi AppTec
    --  WuXi Biologics
    --  Wuxi Biortus Biosciences
    --  WuXi Venture Capital
    --  X-37
    --  X-Chem
    --  XtalPi
    --  Y Combinator
    --  Yael Capital
    --  Yale School of Medicine
    --  YITU Technology
    --  Yonsei University College of Medicine
    --  Yuhan
    --  YunFeng Capital
    --  Zastra
    --  ZebiAI
    --  ZhenFund

For more information about this report visit https://www.researchandmarkets.com/r/j28wjg

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-ai-based-drug-discovery-market-report-2021-current-market-landscape-and-future-potential-of-the-players-engaged-in-offering-ai-based-services-platforms-and-tools---forecast-to-2030-301231782.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav PIR Launches New Institute to Combat DNS Abuse | Feb 25, 2021
Nav Quad9 public domain name service moves to Switzerland for maximum internet privacy protection | Feb 25, 2021
Nav Author Terence Thomas's book "Outer Domain" is a richly detailed futuristic fantasy following a bold mission to investigate a mystery at the outer limits of the galaxy | Feb 25, 2021
Nav Z-Wave Tech-enabled Smart Shades in Vogue, Sales Set to Grow at 16.5% in 2021: Fact.MR's New Study | Feb 25, 2021
Nav Center for Internet Security Funds No-Cost Service to Help Protect all U.S. Private Hospitals Against Ransomware | Feb 25, 2021
Nav Viasat First-to-Certify its High-Speed Network Encryption Device with the New National Security Agency Cryptographic Interoperability Standard | Feb 25, 2021
Nav eBrevia, a DFIN Company, Expands Contract Management Features with Box Integration | Feb 25, 2021
Nav Worldwide Cell Line Development and Characterization Services Industry to 2030 - Featuring BioReliance, Charles River Laboratories & Molecular Diagnostic Services Among Many More | Feb 25, 2021
Nav Revenue Opportunities Are Missed When The C-suite Doesn't Pay Attention, Says New Clarivate Report | Feb 25, 2021
Nav The #ShareTheMicinCyber Campaign Brings Awareness to Black Women Influencing Cybersecurity and Privacy | Feb 25, 2021
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News